Biotech Lab 4.0
Vaccine development by design
A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.
AchilleS Vaccines Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.
AchilleS Vaccines exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.
They Talk About Us
Covid-19: Toscana Life Sciences Sviluppo annuncia l’avvio della sperimentazione clinica per la cura a base di anticorpi monoclonali
I test di fase I coinvolgeranno 30 volontari sani mentre nelle fasi successive la sperimentazione riguarderà qualche centinaio di pazienti con infezione da coronavirus SARS-CoV-2 Pubblicato
Siena, 19 February 2021 – Diesse Diagnostica Senese and AchilleS Vaccines today announced the signing of a strategic agreement under which Diesse develops diagnostics tests